FCA VI Closes with $55M and Adds to the Investment Team

FCA Venture Partners is pleased to announce the completion of fundraising for its sixth fund, FCA Venture Partners VI, on April 27th. The Fund closed with $55M of committed capital and has already made investments in five portfolio companies. Consistent with its predecessor fund, FCA VI will focus on early to growth stage companies in the healthcare IT and technology sectors with disruptive, scalable business models.

Clinical Ink To Accelerate Innovation And Growth With Major Investment By NovaQuest Private Equity

Clinical Ink, the pioneering provider of eSource and next-generation ePRO/eCOA solutions for clinical development, today announced that the private equity team at NovaQuest Capital Management, L.L.C. ("NovaQuest") has acquired a majority of the outstanding shares of the company from existing investors and provided a substantial infusion of additional growth capital. The deep clinical, operational, and financial resources of NovaQuest will allow Clinical Ink to aggressively pursue growth opportunities and fuel investment in new products and operational capabilities.

Absolute Antibody and Kerafast Merge to Increase Access to Unique Reagents and Recombinant Antibody Technology

Absolute Antibody Ltd., an Oxford, UK-based company with a vision to make recombinant antibody technology accessible to all, and Kerafast Inc., a Boston, MA-based company with a mission to facilitate access to unique laboratory-made reagents, today announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.

ChartWise Medical Systems Receives KLAS CDI Software Category Leader Distinction for Third Consecutive Year

For the third consecutive year, ChartWise has been named a Category Leader in the Clinical Documentation Improvement Software segment in the 2018 Best in KLAS: Software & Services report. The prestigious and highly coveted Category Leader designation is reserved for vendor solutions that lead select market segments in which at least two products meet a minimum level of KLAS Konfidence.

Procured Health Is Now Lumere

My colleagues and I founded Procured Health in 2012 to assist hospitals and physicians in their efforts to make evidence-based and data-driven device selection and utilization decisions. Over time, as value-based care has become a reality, we’ve broadened our focus to more holistically guide clinicians and administrative leaders in not only devices but also in medication utilization. Additionally, we have launched new and innovative professional services. As a result, we felt our identity needed to better represent this expanded scope and mission. Watch a video to learn more about our unique clinical approach.